Addiction as a cardiometabolic disease: a neurocardiometabolic framework and the emerging role of GLP-1 receptor therapies
{{output}}
Substance-use disorders are major accelerators of cardiometabolic disease, yet this dimension remains insufficiently recognized within addiction care. Individuals with substance-use disorders frequently exhibit hypertension, adverse lipid profiles, visceral ad... ...
